Exact Sciences Corp (EXAS)
143.58
-10.35 -6.72%
NASDAQ
Jan 26, 13:19
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 1.321B |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | -2.21 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | -333.75M |
Profitability | |
Gross Profit Margin (Quarterly) | 76.71% |
Profit Margin (Quarterly) | -53.85% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0% |
Price and Valuation | |
Market Cap | 24.23B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 15.98 |
PE Ratio | -- |
Price to Book Value | 10.37 |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | 0.6756 |
Free Cash Flow (Quarterly) | 67.45M |
Return on Equity | Upgrade |
View All EXAS News
News
-
WireHeadlineTime (ET)
-
Yahoo01/24 23:11
-
MT Newswires01/21 09:17
-
SA Breaking News01/20 12:00
-
Yahoo01/14 12:34
-
Yahoo01/14 12:16
-
MT Newswires01/13 15:16
-
PR Newswire01/13 14:45
-
Yahoo01/13 06:30
-
SA Breaking News01/12 15:48
-
PR Newswire01/12 14:45
-
SA Breaking News01/12 14:43
-
SA Breaking News01/12 14:43
-
Yahoo01/12 12:48
-
PR Newswire01/12 10:55
-
MT Newswires01/12 10:34
-
Yahoo01/12 08:32
-
MT Newswires01/11 16:00
-
Yahoo01/11 11:01
-
MT Newswires01/11 04:09
-
SA Breaking News01/11 02:06
View All Events
Events
Date | Type | Description |
---|---|---|
02/11/2021 | Earnings | Exact Sciences Corp Fourth Quarter Earnings for 2020 Release |
02/11/2021 17:00 EST | Misc | Exact Sciences Corp Fourth Quarter Earnings Conference Call for 2020 |
10/29/2020 17:00 EDT | Misc | Exact Sciences Corp Third Quarter Earnings Conference Call for 2020 |
10/29/2020 | Earnings | Exact Sciences Corp Third Quarter Earnings Result for 2020 |
07/30/2020 17:00 EDT | Misc | Exact Sciences Corp Second Quarter Earnings Conference Call for 2020 |
07/30/2020 | Earnings | Exact Sciences Corp Second Quarter Earnings Result for 2020 |
07/23/2020 11:00 EDT | Misc | Exact Sciences Corp Annual General Meeting for 2019 |
05/06/2020 17:00 EDT | Misc | Exact Sciences Corp First Quarter Earnings Conference Call for 2020 |
05/06/2020 | Earnings | Exact Sciences Corp First Quarter Earnings Result for 2020 |
02/21/2020 | Misc | Exact Sciences Corp Annual Report for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.exactsciences.com
- Investor Relations URL: http://investor.exactsciences.com/investor-relations/default.aspx
- HQ State/Province: Wisconsin
- Sector: Healthcare
- Industry: Diagnostics & Research
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Feb. 11, 2021
- Last Earnings Release: Oct. 29, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 143.58 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Top Fund Holders
Symbol | Name | Weighting |
---|---|---|
BBH | VanEck Vectors Biotech ETF | 4.62% |
DFRIX | Delaware Smid Cap Growth R | 3.99% |
ARKG | ARK Genomic Revolution ETF | 3.58% |
GOFFX | Invesco Global Opp R5 | 3.39% |
FBT | First Trust NYSE Arca Biotech ETF | 3.34% |
ETCGX | Eventide Gilead C | 2.96% |
APDMX | Artisan Mid Cap Advisor | 2.41% |
TRUZX | T. Rowe Price New Horizons Z | 2.07% |
HGOFX | Hartford Growth Opportunities F | 1.79% |
FXH | First Trust Health Care AlphaDEX® ETF | 1.70% |
ARKK | ARK Innovation ETF | 1.62% |
XBI | SPDR® S&P Biotech ETF | 0.97% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- EXAS Tweets Stocktwits
Advertisement